Nephro Care
NEPHROCARE NSE
Nephro Care
Healthcare ServicesNSE: NEPHROCARE Hospitals
Key Fundamentals
SMEHospitalsHealthcare ServicesMarket Cap
₹153 Cr
Volatility
Moderate
P/E Ratio
44.8
EBITDA
₹8.32 Cr
Return on Equity
6.8%
Debt to Equity
0
Book Value
₹34.49
52W High
₹170.5
52W Low
₹50.05
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.7% over last 3 years.
Growth Rate
Revenue Growth
86.41% higher than
3Y
Net Income Growth
-10.83% lower than
3Y
Cash Flow Change
759% higher than
3Y
ROE
-77.31% lower than
3Y
ROCE
-78.21% higher than
3Y
EBITDA Margin (Avg.)
-40.75% higher than
3Y
Quarterly Results
| Particulars | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 17.33 | 22.66 | 26.75 | 29.19 |
| Expenses | 16.73 | 20.75 | 24.73 | 25.57 |
| Operating Profit | 0.6 | 1.91 | 2.02 | 3.62 |
| OPM % | 3.46% | 8.43% | 7.55% | 12.4% |
| Other Income | 0.05 | 0.08 | 0.83 | 0.22 |
| Interest | 0.14 | 0.03 | -0.01 | 0.03 |
| Depreciation | 1.16 | 1.4 | 1.56 | 1.19 |
| PBT | -0.65 | 0.56 | 1.3 | 2.62 |
| Tax % | 0% | 25% | 23.08% | 38.17% |
| Net Profit | -0.65 | 0.42 | 1 | 1.61 |
| EPS in Rs | -0.39 | 0.25 | 0.61 | 0.98 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | 88.73 |
| Expenses | 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | 80.41 |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 | 8.32 |
| OPM % | 3.7% | 8.24% | 4.09% | 20.07% | 23.76% | 12.75% | 9.38% |
| Other Income | 0.01 | 0.01 | -0.01 | 0 | 0.28 | 1.53 | 1.55 |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 | 0.16 |
| Depreciation | 0 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 | 5.07 |
| PBT | -0.01 | 0.12 | 0 | 2.58 | 6.13 | 4.83 | 4.64 |
| Tax % | 0% | 25% | — | 7.75% | 28.06% | 24.64% | 27.37% |
| Net Profit | -0.01 | 0.09 | -0.01 | 2.37 | 4.41 | 3.64 | 3.37 |
| EPS in Rs | -10 | 90 | -0.2 | 47.4 | 3.71 | 2.21 | 2.04 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.5 | 0.5 | 11.9 | 16.49 | 16.49 |
| Reserves | 0.07 | 0.01 | 0 | 2.03 | 3.12 | 37 | 40.37 |
| Borrowings | 0.4 | 0.69 | 2.54 | 2.48 | 0 | 0 | 0 |
| Other Liabilities | 0.3 | 0.42 | 1.6 | 3.25 | 5.94 | 14.79 | 15.81 |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
| Fixed Assets | 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.48 | 34.12 |
| CWIP | 0 | 0.45 | 1.9 | 0 | 0.86 | 0.61 | 0.43 |
| Investments | 0.24 | 0 | 0 | 2 | 6.51 | 18.58 | 11.82 |
| Other Assets | 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | 26.3 |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | — | 0.23 | 0.62 | 4.12 | 0.91 | 7.82 | 2.21 |
| Investing | — | -0.06 | -2.81 | -2.33 | -7.54 | -39.56 | -0.48 |
| Financing | — | 0.28 | 2.32 | -0.08 | 5.6 | 35.1 | 0 |
| Net Cash Flow | — | 0.44 | 0.13 | 1.71 | -1.03 | 3.37 | 1.73 |
| Free Cash Flow | — | 0.16 | -2.28 | 3.62 | -2.38 | -21.98 | -5.59 |
| CFO/OP | — | 133 | 493 | 121 | 50 | 154 | 48 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 20.28 | 0.85 | 2.01 | 25.61 | 24.85 |
| Inventory Days | — | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | 31.68 |
| Days Payable | — | 94.19 | 113 | 69.03 | 75.17 | 107 | 92.84 |
| Cash Conversion Cycle | 0 | -85.36 | -51.24 | -32.93 | -59.09 | -47.33 | -36.31 |
| Working Capital Days | -169 | -88.24 | -125 | -56.81 | -36.86 | -51.23 | 37.1 |
| ROCE % | — | 25.21% | 1.6% | 65.84% | 60.41% | 11.27% | 8.7% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nephro Care insights
54 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Closure of operations
8 Sep - DAD unit in Kolkata will cease operations and vacate by 15 September 2026. 8 Sep - DAD unit in Kolkata will cease operations and vacate by 15 September 2026.
2
Reply to Clarification- Financial results
1 Sep - Clarifies identical Q1 FY27 standalone and consolidated results due to pre-operative subsidiary Vivacity. 1 Sep - Clarifies identical Q1 FY27 standalone and consolidated results due to pre-operative subsidiary Vivacity.
3
Clarification - Financial Results
28 Aug - Exchange has sought clarification from Nephro Care India Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. … 28 Aug - Exchange has sought clarification from Nephro Care India Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. …
4
Shareholders meeting
26 Aug - FY2025-26 annual report filed; 12th AGM on 25 September 2026 via VC/OAVM. 26 Aug - FY2025-26 annual report filed; 12th AGM on 25 September 2026 via VC/OAVM.
5
Updates
26 Aug - Book closure from 19-25 Sep 2026; AGM on 25 Sep 2026 with remote e-voting. 26 Aug - Book closure from 19-25 Sep 2026; AGM on 25 Sep 2026 with remote e-voting.
Frequently Asked Questions about Nephro Care
What does Nephro Care India Ltd do?
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes
in the treatment of kidney- related diseases[1]
Where is Nephro Care India Ltd (NEPHROCARE) listed?
Nephro Care India Ltd trades as NEPHROCARE on the NSE.
Which sector does Nephro Care India Ltd belong to?
Nephro Care India Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the market capitalisation of Nephro Care India Ltd?
Nephro Care India Ltd has a market capitalisation of ₹152.58 Cr, which places it in the Small Cap band.
What is the PE ratio of Nephro Care India Ltd?
Nephro Care India Ltd trades at a PE ratio of 44.80, against a book value of ₹34.49 per share.
What is the 52-week high and low of Nephro Care India Ltd?
Over the last 52 weeks Nephro Care India Ltd has traded between ₹50.05 and ₹170.5.
What is the Return on Equity (ROE) of Nephro Care India Ltd?
Nephro Care India Ltd reported a return on equity of 6.80%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes in the treatment of kidney- related diseases[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEPHROCARE.md for Nephro Care India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.